Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olmesartan Medoxomil

FDA-approved product (tablet, oral), marketed as Benicar, Olmesartan Medoxomil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Olmesartan Medoxomil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olmesartan Medoxomil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olmesartan Medoxomil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

    NCT02407210 · start 2015-01

    Registered record
    Registry ID
    NCT02407210
    Conditions
    Essential Hypertension
    Interventions
    azilsartan; Olmesartan medoxomil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-01
    Completion
    Not recorded
    Enrolment
    304

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    Interventionazilsartan; Olmesartan medoxomil
    PhasePhase 3
    Registry statusUnknown

  • Medication Adherence and "True" Resistance in Patients With Resistant Hypertension

    NCT02128386 · start 2014-02

    Registered record
    Registry ID
    NCT02128386
    Conditions
    Hypertensive Disease; Hypertension, Resistant to Conventional Therapy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-02
    Completion
    2016-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertensive Disease; Hypertension, Resistant to Conventional Therapy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Angiotensin II Antagonist in Severe Sepsis

    NCT01992796 · start 2014-01

    Registered record
    Registry ID
    NCT01992796
    Conditions
    Severe Sepsis
    Interventions
    Irbesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2017-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Sepsis
    InterventionIrbesartan
    PhasePhase 3
    Registry statusUnknown

  • A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

    NCT01870739 · start 2013-10

    Registered record
    Registry ID
    NCT01870739
    Conditions
    Hypertension
    Interventions
    sacubitril/valsartan (LCZ696); olmesartan; placebo to sacubitril/valsartan (LCZ696); placebo to olmesartan; Amlodipine (Optional)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2015-06
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionsacubitril/valsartan (LCZ696); olmesartan; placebo to sacubitril/valsartan (LCZ696); placebo to olmesartan +1 more
    PhasePhase 2
    Registry statusCompleted

  • Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

    NCT01692301 · start 2012-12

    Registered record
    Registry ID
    NCT01692301
    Conditions
    Hypertension
    Interventions
    LCZ696; Olmesartan; LCZ696 matching placebo; Olmesartan matching placebo; amlodipine; hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2015-04
    Enrolment
    454

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionLCZ696; Olmesartan; LCZ696 matching placebo; Olmesartan matching placebo +2 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical Study for Patients With Hypertension Associated With Dyslipidemia

    NCT01764295 · start 2012-09

    Registered record
    Registry ID
    NCT01764295
    Conditions
    Hypertension; Dyslipidemia
    Interventions
    DWJ1276; Olmesartan; Rosuvastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Dyslipidemia
    InterventionDWJ1276; Olmesartan; Rosuvastatin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

    NCT01615198 · start 2012-08

    Registered record
    Registry ID
    NCT01615198
    Conditions
    Essential Hypertension
    Interventions
    Olmesartan; Placebo; LCZ696
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08
    Completion
    2013-07
    Enrolment
    588

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionOlmesartan; Placebo; LCZ696
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

    NCT01599104 · start 2012-06

    Registered record
    Registry ID
    NCT01599104
    Conditions
    Essential Hypertension
    Interventions
    LCZ696; Olmesartan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2013-04
    Enrolment
    1,161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionLCZ696; Olmesartan; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan

    NCT01552954 · start 2012-02

    Registered record
    Registry ID
    NCT01552954
    Conditions
    Hypertension; Chronic Kidney Disease; Microalbuminuria
    Interventions
    Intensive education of low salt diet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-10
    Enrolment
    269

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Chronic Kidney Disease; Microalbuminuria
    InterventionIntensive education of low salt diet
    PhasePhase 4
    Registry statusCompleted

  • Resistant Arterial Hypertension Cohort Study

    NCT01083017 · start 2011-04

    Registered record
    Registry ID
    NCT01083017
    Conditions
    Hypertension; Essential Hypertension; Resistant Hypertension
    Interventions
    chlorthalidone; motivational intervention for non-compliant individuals; standardized anti-hypertensive treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    2017-05
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Essential Hypertension; Resistant Hypertension
    Interventionchlorthalidone; motivational intervention for non-compliant individuals; standardized anti-hypertensive treatment
    PhaseNot recorded
    Registry statusCompleted

  • Xirtam H Combination In the Treatment of Hypertension Evaluation Study.

    NCT01219556 · start 2010-11

    Registered record
    Registry ID
    NCT01219556
    Conditions
    Hypertension
    Interventions
    Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-11
    Completion
    2013-02
    Enrolment
    8,704

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionOlmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
    PhaseNot recorded
    Registry statusCompleted

  • Recurrent Stroke Prevention Clinical Outcome Study

    NCT01198496 · start 2010-10

    Registered record
    Registry ID
    NCT01198496
    Conditions
    Hypertension; Stroke; Blood Pressure
    Interventions
    Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-10
    Completion
    2019-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Stroke; Blood Pressure
    InterventionLosartan, Losartan and HCTZ, Amlodipine , Spironolactone
    PhasePhase 4
    Registry statusUnknown

  • Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

    NCT01200407 · start 2010-06-09

    Registered record
    Registry ID
    NCT01200407
    Conditions
    Hypertension
    Interventions
    Amlodipine + Olmesartan medoxomil
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2010-06-09
    Completion
    2014-01-04
    Enrolment
    615

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAmlodipine + Olmesartan medoxomil
    PhaseNot recorded
    Registry statusTerminated

  • Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

    NCT01033071 · start 2010-01

    Registered record
    Registry ID
    NCT01033071
    Conditions
    Essential Hypertension
    Interventions
    Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-11
    Enrolment
    1,071

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAzilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Olmesartan Comparison to Losartan in Hypertensive Subjects

    NCT00949884 · start 2009-08

    Registered record
    Registry ID
    NCT00949884
    Conditions
    Hypertension
    Interventions
    olmesartan medoxomil; Placebo; losartan potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-01
    Enrolment
    941

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionolmesartan medoxomil; Placebo; losartan potassium
    PhasePhase 4
    Registry statusCompleted